Clin Endosc.  2017 Nov;50(6):537-545. 10.5946/ce.2017.131.

Diagnosis of Pancreatic Neuroendocrine Tumors

Affiliations
  • 1Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea. hgkim@cu.ac.kr
  • 2Division of Gastroenterology, Department of Medicine, Icahn School of Medicine, The Mount Sinai Medical Center, New York, NY, USA.

Abstract

Pancreatic neuroendocrine tumors (PNETs) are relatively rare; however, the incidence has increased over the last few decades. They are classified as functional or non-functional tumors according to the presence of associated clinical symptoms. The majority are non-functional tumors. For classification and staging, the World Health Organization 2010 classification system is the most commonly accepted. Chromogranin A is the most sensitive marker but has insufficient specificity. In general, PNETs are hypervascular tumors, and multiphasic contrast-enhanced computed tomography is considered the first choice for imaging study. Multiphasic magnetic resonance imaging can detect PNETs smaller than 2 cm and small liver metastasis compared with other modalities. Somatostatin receptor scintigraphy is often used in cases where functional PNETs are suspected. Positron emission tomography (PET) scan with 18F-fluorodeoxyglucose cannot visualize PNETs, but PET with 68-Ga DOTATATE can. Endoscopic ultrasonography can characterize smaller PNETs using contrast and confirm histology through fine needle aspiration or biopsy. In this article, we review the characteristics of grading systems and diagnostic modalities commonly used for PNETs.

Keyword

Pancreatic neuroendocrine tumor; World Health Organization classification; Computed tomography; Magnetic resonance imaging; Endoscopic ultrasonography

MeSH Terms

Biopsy
Biopsy, Fine-Needle
Chromogranin A
Classification
Diagnosis*
Endosonography
Incidence
Liver
Magnetic Resonance Imaging
Neoplasm Metastasis
Neuroectodermal Tumors, Primitive
Neuroendocrine Tumors*
Positron-Emission Tomography
Radionuclide Imaging
Receptors, Somatostatin
Sensitivity and Specificity
World Health Organization
Chromogranin A
Receptors, Somatostatin

Figure

  • Fig. 1. Pancreatic neuroendocrine tumor in a 69-year-old female. A 1.0 cm size, round, hyperattenuating mass (yellow arrow) was seen in the pancreas body. The mass was not observed in non-enhanced phase (A), but highly enhanced in the early arterial phase (B). Contrast was washed out in the late arterial (C) and venous phases (D).

  • Fig. 2. Pancreatic neuroendocrine tumor with cystic degeneration in a 70-year-old female. A 4.8 cm size, round, cystic mass (yellow arrow) was seen in the pancreas head. Peripheral enhancement was observed in the early arterial (A) and late arterial phases (B).

  • Fig. 3. Pancreatic neuroendocrine tumor in a 59-year-old male. A 1.5 cm size, round mass (yellow arrow) was seen in the pancreas body. The mass demonstrates low signal intensity relative to the normal high signal intensity of the pancreas on T1-weighted image (A) and high signal intensity on T2-weighted image (B).

  • Fig. 4. Pancreatic neuroendocrine tumor in a 47-year-old female. A 1.2 cm size, round, hyperattenuating mass (yellow arrow) was seen in the pancreas tail on computed tomography (A). The mass was well defined and displayed a hypoechoic, homogeneous pattern on endoscopic ultrasonography (B).

  • Fig. 5. Pancreatic neuroendocrine tumor in a 45-year-old female. A 2.0 cm size, round, hyperattenuating mass (yellow arrow) was seen in the pancreas head on computed tomography (A). The mass was also observed on endoscopic ultrasonography with internal cystic portion (arrow head) (B).

  • Fig. 6. Pancreatic neuroendocrine tumor in a 42-year-old male. A 1.5 cm size, round, hypoechoic, homogeneous mass (yellow arrow) was seen in the pancreas tail on conventional endoscopic ultrasonography (A). After contrast injection, hyperenhancement was observed in the mass on contrast-enhanced endoscopic ultrasonography (B).


Reference

1. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011; 40:1–18, vii.
Article
2. McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surg. 2014; 3:258–275.
3. Solcia E, Sessa F, Rindi G, et al. Classification and histogenesis of gastroenteropancreatic endocrine tumours. Eur J Clin Invest. 1990; 20 Suppl 1:S72–S81.
Article
4. Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014; 25:186–192.
5. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449:395–401.
6. Ellison TA, Wolfgang CL, Shi C, et al. A single institution’s 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg. 2014; 259:204–212.
7. Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American joint committee on cancer staging classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011; 29:3044–3049.
Article
8. Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016; 139:2679–2686.
Article
9. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008; 135:1469–1492.
Article
10. Vezzosi D, Bennet A, Fauvel J, Caron P. Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol. 2007; 157:75–83.
Article
11. van Beek AP, de Haas ER, van Vloten WA, Lips CJ, Roijers JF, Canninga-van Dijk MR. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004; 151:531–537.
Article
12. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. prospective study of fasting serum gastrin in 309 patients from the national institutes of health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006; 85:295–330.
13. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore). 1996; 75:53–63.
Article
14. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007; 25:1967–1973.
Article
15. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010; 17:2427–2443.
Article
16. Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf). 2004; 60:644–652.
Article
17. Paik WH, Ryu JK, Song BJ, et al. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm. J Korean Med Sci. 2013; 28:750–754.
Article
18. Vinik AI, Silva MP, Woltering EA, Go VL, Warner R, Caplin M. Biochemical testing for neuroendocrine tumors. Pancreas. 2009; 38:876–889.
Article
19. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999; 86:858–865.
Article
20. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011; 18 Suppl 1:S17–S25.
Article
21. Pereira PL, Roche AJ, Maier GW, et al. Insulinoma and islet cell hyperplasia: value of the calcium intraarterial stimulation test when findings of other preoperative studies are negative. Radiology. 1998; 206:703–709.
Article
22. Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology. 1998; 206:143–150.
Article
23. Singhi AD, Chu LC, Tatsas AD, et al. Cystic pancreatic neuroendocrine tumors: a clinicopathologic study. Am J Surg Pathol. 2012; 36:1666–1673.
24. Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012; 26:803–818.
Article
25. Herwick S, Miller FH, Keppke AL. MRI of islet cell tumors of the pancreas. AJR Am J Roentgenol. 2006; 187:W472–W480.
Article
26. Singh S, Law C. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2012; 6:313–334.
Article
27. Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol. 2003; 180:121–128.
Article
28. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations. Neuroendocrinology. 2009; 90:167–183.
Article
29. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005; 23:70–78.
Article
30. Okabayashi T, Shima Y, Sumiyoshi T, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013; 19:829–837.
Article
31. Caramella C, Dromain C, De Baere T, et al. Endocrine pancreatic tumours: which are the most useful MRI sequences? Eur Radiol. 2010; 20:2618–2627.
Article
32. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990; 323:1246–1249.
Article
33. Fjällskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B, Janson ET. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol. 2003; 20:59–67.
Article
34. de Herder WW, Kwekkeboom DJ, Valkema R, et al. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest. 2005; 28(11 Suppl International):132–136.
35. Zimmer T, Stölzel U, Bäder M, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut. 1996; 39:562–568.
Article
36. Garin E, Le Jeune F, Devillers A, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009; 50:858–864.
Article
37. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010; 16:978–985.
Article
38. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007; 34:1617–1626.
Article
39. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010; 51:875–882.
Article
40. Khashab MA, Yong E, Lennon AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc. 2011; 73:691–696.
Article
41. James PD, Tsolakis AV, Zhang M, et al. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. Gastrointest Endosc. 2015; 81:848–856.e1.
Article
42. Leelasinjaroen P, Manatsathit W, Berri R, Barawi M, Gress FG. Role of preoperative endoscopic ultrasound-guided fine-needle tattooing of a pancreatic head insulinoma. World J Gastrointest Endosc. 2014; 6:506–509.
Article
43. Lennon AM, Newman N, Makary MA, et al. EUS-guided tattooing before laparoscopic distal pancreatic resection (with video). Gastrointest Endosc. 2010; 72:1089–1094.
Article
44. Park DH, Choi JH, Oh D, et al. Endoscopic ultrasonography-guided ethanol ablation for small pancreatic neuroendocrine tumors: results of a pilot study. Clin Endosc. 2015; 48:158–164.
Article
45. Han J, Chang KJ. Endoscopic ultrasound-guided direct intervention for solid pancreatic tumors. Clin Endosc. 2017; 50:126–137.
Article
46. Braden B, Jenssen C, D’Onofrio M, et al. B-mode and contrast-enhancement characteristics of small nonincidental neuroendocrine pancreatic tumors. Endosc Ultrasound. 2017; 6:49–54.
Article
47. Sakamoto H, Kitano M, Suetomi Y, Maekawa K, Takeyama Y, Kudo M. Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas. Ultrasound Med Biol. 2008; 34:525–532.
Article
Full Text Links
  • CE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr